Principal Financial Group’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-13,068
| Closed | -$309K | – | 2520 |
|
|
2023
Q4 | $309K | Buy |
13,068
+2,723
| +26% | +$48.5K | ﹤0.01% | 2054 |
|
|
2023
Q3 | $154K | Sell |
10,345
-1,234
| -11% | -$16.4K | ﹤0.01% | 2205 |
|
|
2023
Q2 | $127K | Buy |
+11,579
| New | +$108K | ﹤0.01% | 2254 |
|
|
2021
Q4 | – | Sell |
-13,684
| Closed | -$50K | – | 2669 |
|
|
2021
Q3 | $50K | Sell |
13,684
-2,219
| -14% | -$8.74K | ﹤0.01% | 2538 |
|
|
2021
Q2 | $69K | Buy |
15,903
+602
| +4% | +$2.67K | ﹤0.01% | 2554 |
|
|
2021
Q1 | $69K | Buy |
15,301
+1,077
| +8% | +$5.8K | ﹤0.01% | 2442 |
|
|
2020
Q4 | $82K | Buy |
+14,224
| New | +$108K | ﹤0.01% | 2372 |
|
|
2020
Q2 | – | Sell |
-20,686
| Closed | -$31K | – | 2376 |
|
|
2020
Q1 | $31K | Buy |
20,686
+10,658
| +106% | +$17.9K | ﹤0.01% | 2170 |
|
|
2019
Q4 | $20K | Buy |
+10,028
| New | +$37.7K | ﹤0.01% | 2227 |
|
|
2018
Q4 | – | Sell |
-31,276
| Closed | -$347K | – | 2325 |
|
|
2018
Q3 | $347K | Buy |
31,276
+573
| +2% | +$7.12K | ﹤0.01% | 2045 |
|
|
2018
Q2 | $412K | Buy |
+30,703
| New | +$384K | ﹤0.01% | 2004 |
|
Other funds holding CBAY
Principal Financial Group's CBAY Position: Q1 2024 in Review
Principal Financial Group sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 13,068 shares — an estimated $309K sold.
Principal Financial Group first reported a position in CBAY in Q2 2018 and held it in 11 quarters. The position peaked at $412K in Q2 2018. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Principal Financial Group reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Principal Financial Group sold 13,068 Cymabay Therapeutics shares in Q1 2024, an estimated $309K.
- Principal Financial Group first reported a position in Cymabay Therapeutics in Q2 2018 and held it in 11 quarters.
- Principal Financial Group's Cymabay Therapeutics position peaked at $412K in Q2 2018.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Principal Financial Group's 13F filing for Q1 2024, filed 29 Apr 2024.